Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Aptevo Therapeutics Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- 0 vs. Q2 2022
- Shares held
- 867.6K
- +71.9K (+9.0%) vs. Q2 2022
- Total value
- $2.63M
- −$213.0K (−7.5%) vs. Q2 2022
- New holders
- 3
- 6 more added
- Sold out
- 3
- 4 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $224.3K |
| Q1 2026 | 9 | $229.7K |
| Q4 2025 | 11 | $191.4K |
| Q3 2025 | 12 | $717.1K |
| Q2 2025 | 7 | $45.9K |
| Q1 2025 | 8 | $22.8K |
| Q4 2024 | 13 | $208.7K |
| Q3 2024 | 19 | $231.1K |
| Q2 2024 | 18 | $599.1K |
| Q1 2024 | 10 | $12.4K |
| Q4 2023 | 29 | $349.7K |
| Q3 2023 | 26 | $1.13M |
| Q2 2023 | 23 | $1.36M |
| Q1 2023 | 24 | $1.82M |
| Q4 2022 | 27 | $2.27M |
| Q3 2022 | 27 | $2.63M |
| Q2 2022 | 27 | $2.85M |
| Q1 2022 | 24 | $4.76M |
| Q4 2021 | 23 | $5.99M |
| Q3 2021 | 26 | $42.1M |
| Q2 2021 | 29 | $65.5M |
| Q1 2021 | 34 | $89.7M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Aptevo Therapeutics Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 238,844 | $726.0K | 0.00% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 146,900 | $447.0K | 0.00% | +600+0.4% | Added |
| Cantor Fitzgerald, L. P. | 133,700 | $406.0K | 0.01% | +133,700 | New |
| Renaissance Technologies LLC | 68,386 | $208.0K | 0.00% | −1,500−2.1% | Reduced |
| Geode Capital Management, LLC | 52,961 | $161.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 48,046 | $146.0K | 0.00% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 46,200 | $141.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 28,421 | $86.0K | 0.01% | +15,653+122.6% | Added |
| Bank of New York Mellon Corp | 20,697 | $63.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 18,814 | $57.0K | 0.00% | −3,458−15.5% | Reduced |
| Northern Trust Corp | 17,515 | $53.0K | 0.00% | +572+3.4% | Added |
| Citadel Advisors LLC | 16,776 | $51.0K | 0.00% | +16,776 | New |
| Franklin Resources Inc | 10,997 | $33.0K | 0.00% | +209+1.9% | Added |
| State Street Corp | 10,941 | $33.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,808 | $9.00K | 0.00% | +2,808 | New |
| Bank of America Corp | 1,954 | $6.00K | 0.00% | +1,948+32,466.7% | Added |
| Wells Fargo & Company | 1,754 | $5.00K | 0.00% | +195+12.5% | Added |
| Royal Bank of Canada | 714 | $2.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 430 | $1.00K | 0.00% | −677−61.2% | Reduced |
| Fifth Third Bancorp | 291 | $1.00K | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 142 | $0 | 0.00% | 00.0% | Unchanged |
| US Bancorp | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Harbour Investments, Inc. | 125 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 10 | $0 | 0.00% | −30−75.0% | Reduced |
| Earnest Partners LLC | 14 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 30 | $0 | 0.00% | 00.0% | Unchanged |
| Truvestments Capital LLC | 95 | $0 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 0 | $0 | 0.00% | −79,001−100.0% | Sold out |
| Veritable, L.P. | 0 | $0 | 0.00% | −15,722−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −155−100.0% | Sold out |